| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Efhd2 |
| Uniprot No | Q96C19 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-240aa |
| 氨基酸序列 | MATDELATKLSRRLQMEGEGGGETPEQPGLNGAAAAAAGAPDEAAEALGS ADCELSAKLLRRADLNQGIGEPQSPSRRVFNPYTEFKEFSRKQIKDMEKM FKQYDAGRDGFIDLMELKLMMEKLGAPQTHLGLKNMIKEVDEDFDSKLSF REFLLIFRKAAAGELQEDSGLCVLARLSEIDVSSEGVKGAKSFFEAKVQA INVSSRFEEEIKAEQEERKKQAEEMKQRKAAFKELQSTFK |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于EFHD2重组蛋白的假想参考文献示例(基于领域常见研究方向模拟，非真实文献)：
---
1. **文献名称**: *"Recombinant EFHD2 Protein Expression and Its Role in Mitochondrial Apoptosis"*
**作者**: Lee S, et al.
**摘要**: 本研究利用大肠杆菌系统表达并纯化重组EFHD2蛋白，证实其通过结合Bax蛋白调控线粒体依赖性细胞凋亡通路，为神经退行性疾病机制提供新见解。
2. **文献名称**: *"Structural Characterization of EFHD2 Recombinant Protein and Calcium-Dependent Conformational Changes"*
**作者**: Müller R, et al.
**摘要**: 通过X射线晶体学解析重组EFHD2蛋白的钙结合结构域三维结构，揭示其EF-hand基序的钙离子依赖性构象变化，解释其参与细胞内钙信号传导的分子基础。
3. **文献名称**: *"EFHD2 Recombinant Protein Inhibits Cancer Cell Migration via Actin Cytoskeleton Remodeling"*
**作者**: Chen X, et al.
**摘要**: 在HEK293细胞中重组表达EFHD2蛋白，发现其通过结合F-actin抑制乳腺癌细胞迁移，提示EFHD2可能作为肿瘤转移的潜在治疗靶点。
---
注：以上文献为模拟生成，实际研究中请通过PubMed、Web of Science等平台以"EFHD2"和"recombinant protein"为关键词检索真实文献。
**Background of EFHD2 Recombinant Protein**
EFHD2 (EF-hand domain-containing protein 2), also known as Swiprosin-1. is a calcium-binding protein implicated in diverse cellular processes, including apoptosis, cytoskeletal organization, and immune regulation. Structurally, it contains two EF-hand motifs that enable calcium ion binding, modulating its interaction with other proteins and cellular membranes. EFHD2 is ubiquitously expressed, with notable presence in immune cells, neurons, and cancer tissues, suggesting multifaceted roles in physiology and disease.
Research highlights EFHD2's involvement in neurodegenerative disorders, such as Alzheimer’s disease, where it interacts with tau protein and amyloid-beta plaques, potentially influencing pathological aggregation. In immunology, EFHD2 regulates T-cell receptor signaling and actin dynamics, impacting immune cell activation and migration. Its role in cancer remains debated; while some studies associate EFHD2 with tumor suppression via apoptosis induction, others link its overexpression to metastasis in certain cancers, underscoring context-dependent functions.
Recombinant EFHD2 protein, typically produced in *E. coli* or mammalian expression systems, retains calcium-binding capacity and structural integrity, enabling *in vitro* studies. It serves as a tool to investigate EFHD2's interactome, signaling mechanisms, and calcium-dependent conformational changes. Additionally, it aids in developing antibodies or screening compounds targeting EFHD2-related pathways in neurological or oncological therapeutics.
Despite progress, EFHD2's precise molecular mechanisms and therapeutic potential require further exploration, particularly its dual roles in different diseases. Recombinant EFHD2 remains pivotal in bridging structural insights to functional validation, offering a foundation for translational research.
×
